Opthea

Opthea is a global biopharmaceutical company dedicated to improving vision in people with retinal diseases. They are focused on developing novel therapies to treat highly prevalent and progressive retinal diseases, particularly wet age-related macular degeneration (wet AMD). Opthea's lead investigational drug candidate, sozinibercept (OPT-302), is a first-in-class molecule with a novel mechanism of action, targeting VEGF-C / VEGF-D, for use in combination with existing standard-of-care anti-VEGF-A inhibitors.

Opthea's vision is to advance bold therapeutic innovation and inspire transformation in the global retinal community. They are committed to translating their groundbreaking science into products that prevent or treat progressive retinal diseases that can cause blindness. The company has a strong intellectual property portfolio surrounding their lead candidate, sozinibercept (OPT-302), and is currently conducting two pivotal Phase 3 clinical trials for the treatment of wet AMD.

Opthea is a global biopharmaceutical company dedicated to improving and protecting vision in people with retinal diseases. They aim to become the leader in therapeutic innovation for retinal diseases by assembling a world-class team of ophthalmology experts and focusing on scientific innovation to translate discoveries into promising new medicines.

Opthea promotes a collaborative and science-focused culture that values innovation and a relentless pursuit of breakthrough therapies. They strive to create a positive and impactful environment for their employees, fostering a culture of success and leadership in the global retinal care community.